Q3 2025 Management View CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "treatment with inhaled ...

Supportive therapy, like medications to help open the airways and heal infections, can help you live a healthier life and meet many of the challenges of this inherited respiratory condition. Share on ...

A Rhinelander family is navigating treatment, and learning what their sons future looks like, after his Cystic Fibrosis ...

EXCLUSIVE: The Express has campaigned for cystic fibrosis sufferers for six years but now a charity is highlighting the CF ...

Cystic fibrosis (CF) therapeutics refer to treatments designed to manage and alleviate the symptoms of cystic fibrosis, a ...

Over the course of two decades spent developing treatments for the genetic lung disease cystic fibrosis, biologist Fredrick Van Goor has had hundreds of conversations with patients. But he remembers ...

Modulator therapy does not appear to affect the magnitude of lung function impairment or recovery pattern during pulmonary ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

Terry Wright was 54 when he finally understood why he'd been in pain most of his life. His diagnosis with cystic fibrosis, an inherited lung disease, explained the daily vomiting and stomach pain, ...

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...